Laurus Labs PAT at Rs 201.90 cr. in Q2FY21
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings
FDI increased 98% year on year in 2020 and pharma exports grew by 18% in the last financial year
Filing marks first protein-based vaccine submitted to MHRA for authorization
Support from DFC will help produce one billion vaccine doses by the end of 2022
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
This strategic collaboration will enable continued innovation in cancer care
Subscribe To Our Newsletter & Stay Updated